Compare Quest Diagnostics Inc (DGX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Zillow Group Inc Class A — how do they compare? Quest Diagnostics Inc trades at $202.83 (market cap $22.80B), while Zillow Group Inc Class A trades at $33.53 (market cap $7.28B). The key difference: Quest Diagnostics Inc is far larger — about 3.1× Zillow Group Inc Class A's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| DGX | ZG | |
|---|---|---|
Market Cap | $22.80B | $7.28B |
Sector | Health | Media |
52-Week High | $216.02 | $86.76 |
52-Week Low | $166.42 | $29.14 |
Enterprise Value | $28.82B | $6.93B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Zillow Group (ZG) trades at $31.94, down 0.19% with a bearish technical signal. The company shows improving fundamentals with revenue growth to $2.58B in 2025 and a return to profitability with $23M net income. Analyst consensus remains positive with a $57.80 price target, though recent securities class action lawsuits create near-term uncertainty. Technical indicators show the stock trading near support at $31 with resistance at $33.
ZG presents a mixed outlook with strong analyst support but significant legal overhangs. The company's turnaround to profitability and 51% buy rating suggest upside potential, but ongoing litigation regarding anticompetitive practices with Redfin poses substantial risk. Investors should weigh improving fundamentals against regulatory and legal challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
